New research suggests that people who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop conventional diet and exercise programs.
Published data in a major medical journal demonstrates that while obese individuals often shed a large proportion of their body weight while using the jabs, the weight returns at an average rate of nearly a kilo each month after stopping.
"Individuals buying these treatments need to be aware of the danger of rapid weight regain when the treatment concludes," stated researcher Dr. Susan Jebb.
This pace of recovery implies a return to pre-treatment weight within about a year and a half.
Weighing Therapies
The study, which looked at dozens of trials involving thousands of participants, contrasted the effects of the injectable medications with older methods.
Researchers point out that people who lose weight through dieting typically see a more gradual weight regain—around 100 grams monthly—once they finish.
Understanding the Quick Rebound
Doctors believe the way of the injections explains the accelerated weight return.
The injections imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of GLP-1 levels far above than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication means hunger is no longer kept in check, making binge eating far more likely."
An Ongoing Condition?
Health authorities advise the jabs for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Professionals argue that, due to the likelihood of weight regain, the treatment might need to be ongoing.
This view is supported by drug manufacturers, who note that the results "emphasize the long-term nature of excess weight," comparing it to managing conditions like hypertension.
Patient Experiences
People who have stopped the medication describe a sudden return of cravings.
"It was like a switch that goes on and you become ravenous," described an individual.
This difficulty is compounded if users have not adopted lasting lifestyle or habit modifications during treatment.
Widespread Interest
Figures indicate that a significant number of people in the UK have used these injections in the last 12 months, with desire continuing to grow.
- Adoption is greater among females than males.
- The middle-aged age group shows the greatest usage rates.
- Many access the medications through private prescriptions rather than public health services.
Finally, researchers stress that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone fix and lasting health benefits likely depends on ongoing lifestyle changes.
